NCT03217188CompletedPhase 2
Proton Re-Irradiation for Recurrent Head and Neck Cancer
A Phase II Study of Proton Re-Irradiation for Recurrent Head and Neck Cancer
Source: ClinicalTrials.gov · Last updated 23 Mar 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the tumor control and the side effects of using proton therapy for head and neck cancer that has come back.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 87 (actual)
- First submitted
- 11 Jul 2017
- Start date
- 10 Jul 2017
- Primary completion date
- 18 Mar 2026
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Head and neck cancer
- NCT number
- NCT03217188
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 87
- From 10 Jul 2017 to the primary completion date, 18 Mar 2026
- 9 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \<6 months between completion of prior RT and initiation of reirradiation using proton therapy
Other
- Women who are pregnant or lactating
- Inability to comply with study and/or follow-up procedures
Who the study is looking for
- Patient willing and able to provide written informed consent
- Age ≥18 years at the time of consent
- Pathologically confirmed diagnosis of a recurrent or a new primary head and neck cancer
- A history of prior radiation to the head and neck (\>/= 40 Gy, in 2 Gy/fraction equivalent)
- The recurrent or the second primary tumor is unresectable, the patient elects against surgical resection; patients who underwent surgery who has indications for postoperative radiation therapy is also eligible
- Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months after treatment Note: Patient with \<6 months of life expectancy will be treated with palliative QUAD shot radiotherapy and those with \> 6 months of life expectancy will be treated with conventionally fractionated full dose re-irradiation approach. Additional other factors determining which patients will be treated with Quad Shot therapy rather than full dose are if the patients have poor performance status, bulky or diffuse disease, significant medical co-morbidities, and significant metastatic disease burden.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge Coordinator of this site? Confirm its status | Basking Ridge | United States | Unknown status |
| Memorial Sloan Kettering Commack Coordinator of this site? Confirm its status | Commack | United States | Unknown status |
| Memorial Sloan Kettering Westchester Coordinator of this site? Confirm its status | Harrison | United States | Unknown status |
| Baptist Alliance - McI Coordinator of this site? Confirm its status | Miami | United States | Unknown status |
| Memorial Sloan Kettering Monmouth Coordinator of this site? Confirm its status | Middletown | United States | Unknown status |
| Memorial Sloan Kettering Bergen Coordinator of this site? Confirm its status | Montvale | United States | Unknown status |
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| Memorial Sloan Kettering Rockville Centre Coordinator of this site? Confirm its status | Rockville Centre | United States | Unknown status |
| Memorial Sloan Kettering Nassau Coordinator of this site? Confirm its status | Uniondale | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.